All News

Older men are less likely than older women to have their bone mineral density measured and be prescribed treatment for osteoporosis.

Based on recently published results of the REDUCE-IT study, pharmacuetical company Amarin has submitted a supplemental new drug application (sNDA) to the FDA for an expanded label for its leading drug Vascepa. Also, the American Diabetes Association has included the drug in a mid-year update to its 2019 Standards of Medical Care in Diabetes.

Women with multiple sclerosis (MS) who give birth do not face an increased risk of relapses postpartum. New research being presented in May at the American Academy of Neurology annual meeting found the time right after pregnancy is one of the periods in which MS symptoms may not flare back up.

The Leapfrog Group has launched its first annual survey on patient safety and quality in ambulatory surgery centers.

The FDA is warning of a potential seizure risk associated with e-cigarettes, especially among asolescents and young adults; Sorrento Therapeutics is suing its business partner, alleging he purchased and then tried to prevent the release of their cancer drug; states are suing the Trump administration over plans to loosen school lunch nutrition standards.

While medical advances have improved lifespan and quality of life for patients with HIV, there are still opportunities for strategies that address both medication safety and costs.

Today, the Health Care Payment Learning & Action Network (LAN) launched the Roadmap for Driving High Performance in Alternative Payment Models. The roadmap is designed as a customizable, interactive tool to assist healthcare payers, providers, and various stakeholders in navigating alternative payment model (APM) implementation.

Cigna and its pharmacy benefit manager Express Scripts said they are launching a program for patients with diabetes in its commercial plans so that they pay no more than $25 for a 30-day supply of insulin.

Medicare Advantage (MA) plans will see a 2.53% increase in payments in 2020; the FDA is developing a framework for regulatory oversight of artificial intelligence (AI); a federal court is allowing Wisconsin to withdraw 2 lawsuits from the state challenging the Affordable Care Act (ACA).

During National Public Health Week, a webcast held by the American Public Health Association offered perspectives and stories of grassroots movements that are changing the lives of the people in their region.

A House of Representatives subcommittee heard from stakeholders about the impact of the rising cost of insulin.

Insurance status was found to potentially affect whether patients who used emergency department services were transferred to other hospitals, discharged, or admitted to hospitals.

The American Medical Association and the AARP issue briefs in defense of the Affordable Care Act (ACA), while President Trump is delaying an ACA alternative until after the 2020; top hospitals offer unproven stem cell treatments; the measles outbreak hits a new high.

Data from a phase 2 study demonstrated that high-grade neuroendocrine carcinoma had a 42% overall response rate to the combination of nivolumab and ipilimumab.

The availability and affordability of healthcare is the most pressing concern of Americans, Gallup says in latest poll.

A new study in Health Affairs comes within a week of a federal ruling that found Medicaid work requirements in Arkansas and Kentucky failed to meet requirements of the 1965 law creating the program.

A recent literature review assessed the efficacy of beta-blockers to prevent migraine and tension headache. It found that propranolol worked better than placebo for episodic migraine headaches, but the evidence for efficacy in tension headaches was limited.

By providing case management, self-management education, and skills training, integrated disease management is associated with fewer exacerbations and improved quality of life (QOL) among patients with chronic obstructive pulmonary disease (COPD) enagaged in primary care.

CMS approves Utah Medicaid work requirements after a federal judge overturns rules for Arkansas and Kentucky; youth suicide risk in Missouri grows with the shift to managed care; CDC says a goal of eliminating tuberculosis by end of 21st century unlikely.

As novel therapies drive up the cost of drugs, it is becoming increasingly difficult for community oncologists to keep costs below value-based care program targets, according to a new survey from Integra Connect.

A recent study found that aerobic exercise may be associated with a reduced number of migraine days in patients who experience migraine.

Researchers from South Korea said they have developed a next-generation sequencing (NGS) assay to detect somatic mutations, translocations, and germline mutations in a single assay for the purpose of supplementing or replacing conventional tests in patients with myeloid neoplasms.

A comprehensive genomic analysis of acute erythoid leukemia (AEL) found that 45% of patients had mutations in signaling pathways that drive uncontrolled cell growth, and evidence shows these leukemias may respond to existing precision treatments.

The revolution in cancer care isn’t just about the wave of life-saving therapies, or the role of genetics in pinpointing exactly who should get which drug and when. As Ray D. Page, DO, PhD, FACOI, tells it, change also means getting back to the basics, so that the relationship between doctor and patient drives care—not insurance companies or Medicare or rules from the FDA.

A study consisting of interviews and focus groups among patients with relapsed or refractory multiple myeloma brought attention to what patients value about their treatment.

During the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmcy Annual Meeting, held March 25-28, in San Diego, California, managed care professionals from across the globe gathered to discuss opportunities and challenges facing stakeholders in pharmaceutical management, ranging from drug pricing reform to strategies to address the opioid epidemic.

Recent work looking at the response to immune checkpoint blockade (ICB) therapy given before surgery for advanced melanoma found increased infiltration of B cells, a type of white blood cell, in patients who responded to therapy compared with those who did not.